Keld Flintholm Jørgensen

Member of the Board of Directors since April 2022

Education: BSc in Economics & Business Administration and MSc in Business Economics & Auditing, Copenhagen Business School

Background: +20 years of experience within the global pharma industry across different functional areas such as Business Development, Corporate Strategy, Finance and Auditing. Served in several finance leadership positions at Roche from 2000 and until 2011, where he joined Roche Strategic Partnering. From 2017 he was promoted to Global Head of Roche Strategic Partnering and a member of the Roche Pharma’s Late Stage Portfolio Committee. In 2019, Keld joined Lundbeck as EVP and Chief Business Officer, responsible for Corporate Strategy and Business Development. During the past +10 years in BD, Keld has executed M&A’s and partnering deals worth >10 bio USD

Other ongoing assignments: EVP & Chief Business Officer of Lundbeck A/S

Independence: Independent in relation to both the Company and executive management as well as larger shareholders.

Scandion Oncology shares and warrants:
64.271 warrants.